JP2025513855A5 - - Google Patents

Info

Publication number
JP2025513855A5
JP2025513855A5 JP2024560437A JP2024560437A JP2025513855A5 JP 2025513855 A5 JP2025513855 A5 JP 2025513855A5 JP 2024560437 A JP2024560437 A JP 2024560437A JP 2024560437 A JP2024560437 A JP 2024560437A JP 2025513855 A5 JP2025513855 A5 JP 2025513855A5
Authority
JP
Japan
Prior art keywords
cell
pharmaceutical composition
car
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065642 external-priority patent/WO2023201238A1/en
Publication of JP2025513855A publication Critical patent/JP2025513855A/ja
Publication of JP2025513855A5 publication Critical patent/JP2025513855A5/ja
Pending legal-status Critical Current

Links

JP2024560437A 2022-04-11 2023-04-11 結合剤及びその使用方法 Pending JP2025513855A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329664P 2022-04-11 2022-04-11
US63/329,664 2022-04-11
US202263399588P 2022-08-19 2022-08-19
US63/399,588 2022-08-19
PCT/US2023/065642 WO2023201238A1 (en) 2022-04-11 2023-04-11 Binding agents and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025513855A JP2025513855A (ja) 2025-04-30
JP2025513855A5 true JP2025513855A5 (https=) 2026-04-20

Family

ID=86328509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560437A Pending JP2025513855A (ja) 2022-04-11 2023-04-11 結合剤及びその使用方法

Country Status (7)

Country Link
US (1) US20250333515A1 (https=)
EP (1) EP4507794A1 (https=)
JP (1) JP2025513855A (https=)
CN (1) CN119487069A (https=)
AU (1) AU2023254830A1 (https=)
CA (1) CA3248167A1 (https=)
WO (1) WO2023201238A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
SG10201913782UA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
MA40579A (fr) * 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
CN108472365A (zh) 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
US10508143B1 (en) 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
AU2018225164A1 (en) 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
US20200306375A1 (en) 2017-02-22 2020-10-01 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
EP3850013A4 (en) * 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
WO2020113063A1 (en) * 2018-11-30 2020-06-04 Aleta Biotherapeutics Inc. Single domain antibodies against cll-1
AU2020338011A1 (en) 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
JP7512394B2 (ja) * 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16及びclec12aに結合するタンパク質
WO2022047168A1 (en) 2020-08-28 2022-03-03 Vor Biopharma Inc. Compositions and methods for cll1 modification
US20240238344A1 (en) 2020-08-28 2024-07-18 Vor Biopharma Inc. Compositions and methods for cd123 modification
CN113045658B (zh) * 2020-12-11 2021-12-24 广州百暨基因科技有限公司 抗cll1抗体及其应用

Similar Documents

Publication Publication Date Title
JP2025065142A5 (https=)
JP2022109953A5 (https=)
RU2355705C2 (ru) Одноцепочечное цикличное триспецифическое антитело
CN114957475B (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
JP2021177771A5 (https=)
JP2023123502A5 (https=)
JP2023071729A5 (https=)
JP2023139070A5 (https=)
JP2025020138A (ja) 免疫細胞活性化のための二重特異性抗体
JP2024177479A (ja) 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトIgM定常領域
JP2020529841A5 (https=)
JP2023509212A5 (https=)
JP2019530431A5 (https=)
JP2019524100A5 (https=)
JPH05505112A (ja) Aids、arcおよびhiv感染の予防および治療に有用な抗cd4抗体ホモログ
US20230212293A1 (en) Pd-1 agonist multimeric binding molecules
JP2025508343A5 (https=)
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
EP4017533A1 (en) Igm glycovariants
US20210395380A1 (en) Variant antibodies that bind ox40
JP2024544559A5 (https=)
JP2024504728A5 (https=)
TW202233694A (zh) 雙特異性抗體
WO2022057875A1 (zh) 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途
JP2024507693A5 (https=)